Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Iceland Health Focus.
Increasing Demand for Convenient & Hygienic Packaging Solutions in the Pharmaceutical Industry is a Key Growth Driver for the Pharmaceutical Tubes Market; A Report by TNR, The Niche Research
GlobeNewswire, Inc.
·
July 24, 2024
Wilmington, Delaware, July 24, 2024 (GLOBE NEWSWIRE) -- Pharmaceutical tubes are essential packaging components used extensively in the pharmaceutical industry for storing and dispensing various forms of medications, creams, ointments, and gels....
European Commission Approves Duvyzat for the Treatment of Duchenne Muscular Dystrophy
GlobeNewswire, Inc.
·
June 6, 2025
Now approved in the EU, Duvyzat offers an important treatment option for delaying Duchenne muscular dystrophy (DMD) disease progression Duvyzat is an orally administered treatment for DMD in patients 6 years and older who are able to walk The...
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
GlobeNewswire, Inc.
·
June 5, 2025
HYDERABAD, India and REYKJAVIK, Iceland, June 05, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr....
Seaweed Market Worth Observing Growth Rate of 9.5% from 2025 to 2034 | Annie Chun's, Inc., Brandt, Inc., Cargill
EIN Presswire
·
June 17, 2025
WILMINGTON, DE, UNITED STATES, June 17, 2025 /EINPresswire.com/ -- The seaweed market size was valued at $7.5 billion in 2024, and is estimated to reach $18.1 billion by 2034, growing at a CAGR of 9.5% from 2025 to 2034. Seaweed is a diverse...
Oculis to Participate in Upcoming June Investor Conferences
GlobeNewswire, Inc.
·
June 3, 2025
ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet...
Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million
GlobeNewswire, Inc.
·
June 5, 2025
THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA,...
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
GlobeNewswire, Inc.
·
May 23, 2025
Positive CHMP opinion based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicity Opinion follows FDA approval and MHRA conditional marketing...
Oculis Publishes Results of 2025 Annual General Meeting
GlobeNewswire, Inc.
·
June 5, 2025
ZUG, Switzerland, June 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2025 Annual General Meeting held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11,...
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT
GlobeNewswire, Inc.
·
May 2, 2025
REYKJAVIK, Iceland, May 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial...
Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
GlobeNewswire, Inc.
·
April 28, 2025
VYJUVEK approved for the treatment of DEB from birth in Europe Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare professional PITTSBURGH, April 28,...
United Kingdom Falls to 12th Spot in 2025 World Citizenship Index, as Switzerland Claims Top Rank
EIN Presswire
·
June 23, 2025
LONDON, UNITED KINGDOM, June 23, 2025 /EINPresswire.com/ -- The United Kingdom has secured the 12th position in the 2025 World Citizenship Index (WCI), released by CS Global Partners in their much-anticipated annual World Citizenship Report....
Ligand Reports First Quarter 2025 Financial Results
GlobeNewswire, Inc.
·
May 8, 2025
First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial...
Oculis Reports Q1 2025 Financial Results and Provides Company Update
GlobeNewswire, Inc.
·
May 8, 2025
The recent R&D Day (replay) showcased material progress across all three core assets and highlighted potential first-in-class neuroprotection treatment in neuro-ophthalmology, an area of high unmet medical need, thanks to Privosegtor’s (OCS-05)...
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
GlobeNewswire, Inc.
·
May 1, 2025
ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet...
Oculis to Present at Upcoming May Investor Conferences
GlobeNewswire, Inc.
·
May 7, 2025
ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet...
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
GlobeNewswire, Inc.
·
April 28, 2025
VYVGART® is first-and-only targeted IgG Fc-antibody fragment for CIDP First novel mechanism of action for CIDP treatment in more than 30 years CHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trial European Commission...
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
GlobeNewswire, Inc.
·
May 5, 2025
The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April 30, 2025 SELARSDI is approved for all...
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
GlobeNewswire, Inc.
·
May 5, 2025
The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April 30, 2025 SELARSDI is approved for all...
Open Ocean Robotics Launches First USV for Marine CO₂ Removal Monitoring with Sales to Leading Research Institutions
EIN Presswire
·
May 9, 2025
With initial sales to Dalhousie University and Iceland’s Röst Centre, Open Ocean Robotics introduces first USV built for marine carbon removal monitoring. VICTORIA, BRITISH COLUMBIA, CANADA, May 9, 2025 /EINPresswire.com/ -- Open Ocean Robotics...
Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update
GlobeNewswire, Inc.
·
May 7, 2025
Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increase Product Revenues in the first in the first quarter of 2025 reached $109.9 million, compared to...